Universal Peace Federation Convenes Think Tank 2022 Rally of Hope
A wide range of challenges stand in the way of building a stable and relatively peaceful global order for the 21st Century. Recent events related to the U.S. withdrawal from Afghanistan underscore this fact.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210909005818/en/
Dr. Hak Ja Han Moon, co-founder of the Universal Peace Federation addressing the global audience during the virtual 6th Rally of Hope and the launching of “THINK TANK 2022” (Photo: Business Wire)
Of critical importance to the geopolitical dynamics of our time is the ongoing crisis on the Korean Peninsula, which impacts East Asia and the rest of the world. While efforts toward peace have prevented another war in Northeast Asia, the potential for conflict still remains and would involve the U.S., China, Russia, and Japan. It is time for a new strategy to move toward reconciliation and cooperation on the Korean Peninsula.
Who: Think Tank 2022 Rally of Hope online is sponsored by the Universal Peace Federation (upf.org)
When: Sunday, September 12, 2021, 2:30 a.m. CET, Europe & Middle East (Live broadcast from South Korea) or Replay/Highlights: September 12, 2021, 6:00 PM CET
Where: Join the Live Event September 12th, at 02:30 AM (CET)
through this link: https://www.peacelink.live/online/
Join the Highlight Event September 12th, at 06:00 PM (CET)
through Zoom link: http://www.zoom.rallyofhope.eu/
or Live Facebook: http://www.facebook.rallyofhope.eu/
What: Inaugurated in 2020, the Rally of Hope is a series of live-streamed online productions using advanced augmented reality technology to connect millions of global viewers. Featuring prominent world leaders and captivating entertainment, the Rally of Hope is uplifting, actionable and faith-based.
Why: This new and unique program empowers the ordinary citizen who seeks meaningful change in their personal life, family, community, and even globally, by participating in a movement which transcends political, religious, racial, and ideological boundaries.
Previous Rallies of Hope have provided a platform for top experts to speak about the complex issues facing our planet, including: climate change, geopolitical hotspots, challenges of the coronavirus pandemic, honoring veterans of the Korean War on its 70th anniversary, the role of faith in peacebuilding, and much more.
The theme of the Think Tank 2022 Rally of Hope is “Steps Toward Peace in Asia: Focus on Reconciliation and Cooperation on the Korean Peninsula.” Although the Armistice Agreement brought an end to the hostilities, the Korean Peninsula continues to be a “storm center” for peace and security in the region. World leaders will speak about the risks and opportunities of resolving issues on the Korean Peninsula and steps toward peace in Asia.
Keynote Speakers: Kingdom of Cambodia Prime Minister Hun Sen, European Commission President
José Manuel Barroso (2004-2014), Republic of the Philippines President Gloria Macapagal Arroyo (2000-2010), Republic of India Prime Minister H.D. Deve Gowda (1996-1997), Trinidad and Tobago President Anthony Thomas Aquinas Carmona (2013-2018), and Republic of Serbia President Nataša Mićić (2002-2004). UPF Co-Founder Hak Ja Han Moon will offer a special message of hope in her Founder’s Address.
Find out more about the Rally of Hope & Think Tank 2022 here: https://www.rallyofhope.eu
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210909005818/en/
Contact information
Media:
Peter Zoehrer, UPF Media Relations - Europe & Middle East
+43 (0)6645238794
media@europe.upf.org
UPF.ORG & EUME.UPF.ORG
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Sonrotoclax Data at ASH 2025 Confirm Foundational Potential Across B-cell Malignancies8.12.2025 01:00:00 EET | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data on sonrotoclax, a next-generation investigational BCL2 inhibitor, demonstrating meaningful clinical benefit as monotherapy and in combination across B-cell malignancies. These data were featured at the 67th American Society of Hematology (ASH) Annual Meeting & Exposition in Orlando, Florida. The five presentations highlight durable responses in heavily pretreated patients with relapsed/refractory (R/R) mantle cell lymphoma (MCL) and additional studies showing deep, rapid, and sustained undetectable minimal residual disease (uMRD) rates with sonrotoclax-based combinations in patients with treatment-naive chronic lymphocytic leukemia (CLL), highlighting the foundational potential of this medicine. “The data we’re presenting at ASH 2025 are redefining what physicians can expect from sonrotoclax as a next-generation BCL2 inhibitor,” said Amit Agarwal, M.D., Ph.D., Chief Medical
Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 18:00:00 EET | Press release
AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th
CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 14:00:00 EET | Press release
Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships Powering the Summit CoMotion GLOBAL 2025 is hosted by the Saudi Conventions & Exhibitions General Authority (SCEGA), supported by key Saudi
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67 th American Society of Hematology (ASH) Annual Meeting6.12.2025 16:30:00 EET | Press release
Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which Ono obtained exclusive global rights for the development and commercialization of sapablursen. “In the treatment of PV, phlebotomy and cytoreductive therapy are performed as treatments for preventing thrombosis. Phlebotomy is the most common treatment for PV, in which blood
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 16:30:00 EET | Press release
Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition. These findings further reinforce rusfertide’s efficacy and safety and demonstrate durability of response, with 61.9% of patients continuously treated with rusfertide maintaining absence of phlebotomy eligibility from baseline to Week 52. “The 52-week data demonstrated the sustained efficacy of rusfertide, reducing the need for patients to receive phlebotomy while maintaining hematocrit control,” said Dr. Andrew T. Kuykendall, M.D., VERIFY Lead Investigator and Associate Member in the Department of Hematology at Moffitt Cancer Center. “The 32-week VERIFY primary results were already promising, and this deeper understanding of the durability of r
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom